In the fast-evolving landscape of the life science industry, the development of complex biologics like bispecific antibodies, fusion proteins, and antibody-drug conjugate therapies is reshaping the drug development process. With the demand for more targeted and precise medicines on the rise, the journey from DNA to Investigational New Drug (IND) application has become increasingly accelerated, with timelines shrinking to under 15 months.
Biologic therapies have gained prominence in treating a range of conditions, from autoimmune diseases to cancer and neurodegenerative disorders. The market now features intricate molecular formats such as bispecific antibodies targeting two cellular markers, ADC therapies combining antibodies with chemotherapy drugs, and fusion proteins merging functional domains for enhanced therapeutic effects.
To meet the challenges posed by these advancements, Contract Development and Manufacturing Organizations (CDMOs) must adapt their strategies to cater to diverse market demands. Lonza, a global CDMO based in Switzerland, employs a blend of innovative technologies, strategic approaches, and extensive scientific expertise to provide tailored solutions for various stages of drug development, catering to the unique needs of each molecule and customer.
In the highly competitive CDMO landscape, Lonza stands out for its combination of scale, scientific depth, and flexibility in addressing the individual requirements of a diverse clientele. By recognizing that each customer and molecule is unique, Lonza emphasizes the importance of bespoke solutions tailored to specific developmental stages and molecular characteristics.
Specialist teams with profound knowledge in complex biotherapeutic formats play a crucial role in shaping the DNA to IND journey. As the industry gravitates towards novel and intricate molecular structures like bispecific antibodies, the need for specialized expertise in navigating these complexities becomes paramount for successful development.
Lonza’s recent streamlining efforts under the One Lonza strategy aim to consolidate its core strengths into three CDMO platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Leveraging decades of experience, these platforms harness the company’s capabilities in mammalian and microbial services, hybrid chemistry, and cutting-edge technologies to support diverse manufacturing needs.
Early decision-making in drug development can significantly impact the success and efficiency of the overall process. Identifying potential liabilities, optimizing molecular properties, and aligning them with scalable manufacturing strategies are vital steps in avoiding setbacks and expediting the journey to clinical and commercial viability.
By proactively addressing risks in the early stages of development, Lonza assists customers in mitigating program vulnerabilities and devising tailored solutions to enhance the molecule’s performance. Through meticulous planning and risk assessment, potential obstacles can be preemptively managed, reducing the likelihood of costly modifications or process redesigns later in the development cycle.
One of the key focus areas for Lonza is early formulation assessment, where the company utilizes advanced tools and predictive modeling to evaluate molecule stability and compatibility. By combining scientific insights with high-throughput screening capabilities, Lonza facilitates data-driven decision-making to ensure the stability and efficacy of promising drug candidates throughout development.
Lonza’s GS Gene Expression System®, renowned for its scalability and track record of regulatory approvals, plays a pivotal role in expediting development decisions. With a history of bringing over 100 molecules to market, the platform exemplifies Lonza’s commitment to driving innovation and supporting customers from early development phases to commercial success.
Toxicology studies, often a bottleneck in drug development, can significantly impact timelines. Lonza’s rapid tox material supply offerings enable customers to initiate studies promptly, potentially saving up to three months in the toxicology evaluation process. Strategies like pool-based tox batches and early assay development further streamline progress, ensuring timely delivery of high-quality materials for clinical readiness.
Lonza’s integrated approach to early CMC decisions underscores the importance of strategic insights, technological advancements, and risk mitigation in accelerating the IND process with confidence. By combining speed, quality, and regulatory expertise, Lonza empowers biotech companies to navigate the complexities of drug development and achieve regulatory milestones efficiently.
In conclusion, the dynamic landscape of biotech manufacturing operations demands a strategic approach to decision-making, risk management, and collaboration. Lonza’s commitment to innovation, tailored solutions, and regulatory excellence positions it as a trusted partner for companies embarking on the transformative journey from DNA to IND application, ultimately shaping the future of drug development.
Takeaways:
– Early identification and mitigation of potential liabilities in drug candidates are crucial for accelerating the path to clinical and commercial success.
– Advanced formulation assessments, predictive modeling, and high-throughput screening tools play a key role in ensuring molecule stability and compatibility.
– Rapid toxicology material supply offerings can help reduce bottlenecks in toxicology studies, enabling faster progression through the drug development process.
Tags: regulatory, mammalian expression, biotech, formulation, microbiome, toxicology, synthetic biology, process development, gene therapy
Read more on labiotech.eu